Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:medRxiv
Egile Nagusiak: Dupont, Liane, Snell, Luke B., Graham, Carl, Seow, Jeffrey, Merrick, Blair, Lechmere, Thomas, Hallett, Sadie R., Charalampous, Themoula, Alcolea-Medina, Adela, Huettner, Isabella, Maguire, Thomas J. A., Acors, Sam, Almeida, Nathalia, Cox, Daniel, Dickenson, Ruth E., Galao, Rui Pedro, Jimenez-Guardeño, Jose M., Kouphou, Neophytos, Lista, Marie Jose, Pickering, Suzanne, Ortega-Prieto, Ana Maria, Wilson, Harry, Winstone, Helena, Fairhead, Cassandra, Su, Jia, Nebbia, Gaia, Batra, Rahul, Neil, Stuart, Shankar-Hari, Manu, Edgeworth, Jonathan D., Malim, Michael H., Doores, Katie J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cold Spring Harbor Laboratory 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202432/
https://ncbi.nlm.nih.gov/pubmed/34127977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.06.07.21258351
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak